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Case Reportsis of utmost importance to prevent such typical
complications of cardiac tumors as stroke or embolism.
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The St Jude Medical Portico THV (St Jude Medical, Inc,
St Paul, Minn) is the first fully resheathable percutaneous
valve. We report the feasibility of implantation of the
23-mm St Jude Medical Portico THV by the transapical
approach. Despite this encouraging initial experience,
future studies are needed to demonstrate the safety and
efficacy of this new valve.
CLINICAL SUMMARY
An 82-year-old woman was referred to our center for
aortic valve replacement. She was not considered to be a
candidate for surgical aortic valve replacement in the eval-
uation of the heart team because of severe comorbidities
(diabetes, hypertension, anemia, recent myocardial infarc-
tion requiring percutaneous intervention with left main
drug eluting stent implantation, severe peripheral vascular
disease) leading to a predicted risk of perioperative mor-
tality of 7.8 as estimated by Society of Thoracic Surgeonsscore. An echocardiographic assessment confirmed a
severely calcific aortic stenosis (mean gradient 38 mm
Hg; aortic valve area: 0.65 cm2) with normal left ventric-
ular function and an aortic annulus of 19.5 mm. A trans-
catheter aortic valve implantation procedure with the 23-
mm Portico valve through the transapical approach was
planned. Signed, informed consent was obtained for the
procedure and for this publication.
The procedure was performed in the operating room
with general anesthesia and echocardiographic and fluoro-
scopic guidance with a C-arm radiographic system. A
standard transapical approach was carried out, as
described previously.1 Initially, a 7F sheath was inserted
to secure the access site. After a stiff wire was placed in
the descending aorta, the 7F sheath was replaced by a
14F introducer sheath. An aortic valvuloplasty was then
performed with an 18-mm balloon, after which the 24F
(outer diameter) St Jude delivery system with integrated
sheath and mounted Portico valve was inserted through
the apex and placed at the aortic annulus level on the stiff
wire (Figure 1, A). Rapid pacing was not used for valve
deployment. The valve was gradually released by rotating
the thumbwheel in a clockwise direction with a continuous
tension to keep the position of the distal edge of the skirt
at the level of the aortic annulus (Figure 1, B). When 80%
of the valve had been released, the positioning was as-
sessed with several angiographic studies (Figure 1, C,
and Video 1). The valve was recaptured and repositioned
to achieve an optimal position, at which time it was fully
released (Figure 1, D). Balloon postdilatation with a
23-mm balloon was performed because of initial
mild-to-moderate paravalvular aortic regurgitation (PAR).
After balloon and sheath removal, once hemostasis was
complete, the chest was closed in a standard fashion.
The final result showed trivial PAR and correct positioningery c October 2013
FIGURE 1. Angiographic images showing the steps of St Jude Medical Portico THV (St Jude Medical, Inc, St Paul, Minn) implantation and
photographic images of the prosthesis and delivery system. A, The fully sheathed Portico THV. The radiopaque marker is used to guide the valve
positioning. B, The valve is fully functional during the deployment process. C, The Portico valve is fully resheatheable until full deployment. D, Final
result of the Portico THV implantation. E, Detail of the St Jude Medical Portico THV, which consists of 3 pericardial leaflets attached on a nitinol
stent. Note the open cells and pericardial cuff designed to minimize paravalvular aortic regurgitation. F, Delivery system after valve deployment.
Black arrow indicates curved shape of the capsule. White arrow indicates radiopaque marker to guide aortic valve positioning at the level of the
aortic annulus.
Case Reportsof the valve (Video 2). The patient was discharged 7 days
after the procedure without complications.
At 1-month follow-up, the patient was in functional class
II. Echocardiography confirmed correct positioning of the
bioprosthesis with a mean gradient of 6 mmHg, aortic valve
area of 1.8 cm2, and trivial PAR.
DISCUSSION
The St Jude Medical Portico valve is the first fully
resheathable percutaneous valve. It consists of a nitinol
self-expanding stent with open cells partially covered by
a porcine pericardial cuff, to decrease the risk of PAR,
and leaflets of bovine pericardial tissue inserted in a low
position for minimizing the protrusion of the stent into
the left ventricular outflow tract (Figure 1, E). The 24F
delivery system used for transapical approach is composed
of a tapered nose cone, a capsule containing the com-
pressed valve, and a handle with a thumbwheel that allows
the release or resheathing of the valve while rotating
clockwise or counterclockwise, respectively. The inner
shaft contains a radiopaque marker that provides a
reference point and contributes, as does the curved
shape of the capsule, to a better valve alignment in the
aortic annulus (Figure 1, F, white and black arrows,
respectively).The Journal of Thoracic and CaProsthetic valve positioning remains a challenging step
even for expert operators. Improper placement of the stent
valve may contribute to some of the most feared complica-
tions associated with transcatheter aortic valve implanta-
tion, such as stent prosthesis embolization, PAR, mitral
impingement, coronary obstruction, and conduction disor-
ders.2 During recent years, new-generation transcatheter
heart valves have emerged to overcome the shortcomings
of the first-generation valves. The main differences among
new-generation transcatheter valves implanted through the
transapical approach are shown in Table 1. The St Jude
Medical Portico prosthesis is currently the only device
that is fully retrievable until fully deployed. Although that
feature was not used in this case, it would be expected
to be associated with a reduced risk of periprocedural
complications related to malpositioning of the valve
because it allows full control of the valve until final
placement. Still, the potential positive impacts of these
various features remain speculative.
Despite correct positioning of the bioprosthesis, initial
mild-to-moderate aortic regurgitation was observed in
this case, requiring balloon postdilatation, with a final triv-
ial PAR. A high degree of valve calcification precluding
the complete valve expansion may explain this finding.
Inadequate initial radial force represents anotherrdiovascular Surgery c Volume 146, Number 4 e25
TABLE 1. Mean differences between available second- and third-generation valves for use with the transapical approach
Type Frame Leaflets
Valve
level
Delivery
system Repositionable
Fully
retrievable*
Aortic
regurgitation
prevention
Other
advantages
Portico
(St Jude)3
Self-expanding Nitinol Bovine Annular 24F
(sheathless)
Yes Yes Porcine cuff Open cells
preventing
coronary
obstruction;
low leaflet
position
avoiding frame
protrusion in
LVOT;
anticalcification
technology
Engager
(Medtronic)4
Self-expanding Nitinol Bovine Supra-
annular
29F Yes No Control arms
capturing
native leaflets
Control arms
capturing
native leaflets,
preventing
coronary
obstruction;
anatomic
positioning;
commissure
markers
JenaValve
(JenaValve)4
Self-expanding Nitinol Porcine Annular 32F Yes No Clip fixation of
the native
leaflets
Clip fixation of
the native leaflets,
reducing radial
forces in LVOT
and risk of
coronary
obstruction;
anatomic
positioning
Acurate TA
(Symetis)4
Self-expanding Nitinol Porcine Annular 28F No No PET skirt;
‘‘upper crown’’
technique
Valve positioning
marker; easy
deployment
Sapien 3
(Edwards)4
Balloon
expanded
Cobalt
chromium
Bovine Annular 18F No No PET skirt; PET
sealing ring
Anticalcification
technology;
valve positioning
marker
LVOT, Left ventricular outflow tract; PET, polyethylene terephthalate. *Fully retrievable until fully deployed.
Case Reportsspeculative reason. In the recently reported initial experi-
ence with the 23-mm Portico THV implanted by the trans-
femoral approach, however, no postdilatation was used
and only 1 in 10 patients had moderate residual aortic
regurgitation, comparable to results obtained with other
transcatheter valves.3
In addition, the sheathless delivery system used by the St
Jude Medical Portico prosthesis is one of the smallest used
for transcatheter aortic valve implantation by transapical
access, which could prove an advantage in patients with
frail apexes. Despite the lack of observed complications
in this case, however, the absence of a sheath could be
associated with apical tearing when the delivery system ise26 The Journal of Thoracic and Cardiovascular Surgremoved and replaced with a sheath in case of the need of
postdilatation.
In conclusion, this case reports the feasibility of the
23-mm St Jude Medical Portico THV implantation by the
transapical approach. Despite this encouraging initial
experience, future studies including a larger number of
patients are required to demonstrate the safety and
efficacy of this new valve.
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mitral prosthesisAmine Mazine, MD,a Tam Hoang Minh, MD,b Denis Bouchard, MD, FRCSC,a,b and
Philippe Demers, MD, FRCSC,a,b Montreal, Quebec, CanadaSutureless aortic valve replacement (AVR) has recently
emerged as a promising alternative to standard AVR in pa-
tients who have severe aortic stenosis and face a high sur-
gical risk.1 Because of the excellent survival associated
with mechanical mitral valve replacement, it is expected
that in the coming years an increasing number of elderly
patients who are seen for aortic stenosis will have previ-
ously undergone mitral valve replacement. The presence
of a mitral prosthesis is considered a contraindication to
sutureless AVR, however, because it has been speculated
to alter the geometry of the aortic root and left ventricular
outflow tract, thus interfering with deployment and stabil-
ity of the sutureless aortic bioprosthesis. Although trans-
catheter aortic valve implantation (TAVI) in the presence
of a mitral prosthesis has been reported in the literature,2
this to our knowledge is the first case report to describe su-
tureless AVR in a patient with previous mitral valve
replacement.
CLINICAL SUMMARY
A 75-year-old woman was admitted for progressive dys-
pnea of grade III to IV. The patient had a history of mitral
stenosis, for which she had undergone mitral replacement
21 years earlier with a mechanical prosthesis (Carbomedics
size 29 mm; Sorin Biomedica Cardio Srl, Saluggia, Italy).
The history was also positive for hypertension, hyperlipid-
emia, chronic atrial fibrillation, and an embolic stroke at age
39 years, with residual hemiparesis of the left inferior limb.A transesophageal echocardiogram revealed the presence
of severe aortic stenosis, with an aortic valve area of 0.3 cm2
and a mean gradient of 39 mm Hg. The mitral prosthesis
was totally functional, with no mitral regurgitation and a
mean gradient of 3 mm Hg. The length of the aortomitral
continuity was calculated at 10 mm (Figure 1). There was
also severe tricuspid regurgitation. The left ventricular ejec-
tion fraction was 60%.
The logistic euroSCORE II was calculated at 19.7%.
Surgical intervention was scheduled to correct the aortic
stenosis and tricuspid regurgitation. A median sternotomy
was performed, and cardiopulmonary bypass was initiated
with atriobicaval cannulation. The patient underwent
beating-heart tricuspid annuloplasty with a 30-mm
Carpentier-Edwards Physio ring (Edwards Lifesciences
Corp, Irvine, Calif), followed by sutureless AVR with a
23-mm Perceval S sutureless bioprosthesis (Sorin). Aortic
crossclamp and cardiopulmonary bypass times were 31
and 63 minutes, respectively. Weaning from bypass was
easy, and the patient was extubated on the same day.
The postoperative course was uneventful. The patient did
not demonstrate any conduction abnormalities; however,FIGURE 1. Preoperative transesophageal echocardiogram illustrating the
distance between the mitral prosthesis and the aortic annulus.
rdiovascular Surgery c Volume 146, Number 4 e27
